News
Public · Published
ONWARD Medical Delivers Revenue of EUR 2.5M in Q3 2026, with Sustained Commercial Momentum and Strong Clinical Execution
ONWARD Medical reported EUR 2.5M in third-quarter 2026 revenue and a cash balance of EUR 73.4M as of September 30, 2026. It sold or supplied 88 ARC-EX Systems in the quarter, 120% unit growth year over year, with ARC-EX available in more than 170 clinics worldwide.
Published:
Updated:
What happened
ONWARD Medical reported EUR 2.5M in third-quarter 2026 revenue and a cash balance of EUR 73.4M as of September 30, 2026. It sold or supplied 88 ARC-EX Systems in the quarter, 120% unit growth year over year, with ARC-EX available in more than 170 clinics worldwide.
Confirmed
Global impact / market context
Revenue shows the company is generating sales while holding EUR 73.4M in cash available, which funds operations and clinical studies. Unit growth of 120% and wider clinic availability suggest rising adoption of ARC-EX, which can support future revenue and help offset the costs of running trials.
Analyst inference
ONWARD is a neurotechnology company developing therapies for spinal cord injuries. Investors weigh commercial uptake of ARC-EX against spending on the Empower BP pivotal study, which has 31 participants enrolled and 16 recruiting sites, since trial costs consume cash before any future approval or revenue.
Analyst inference
What to watch
- Watch whether ARC-EX unit sales and clinic availability keep growing from 88 units and more than 170 clinics, since wider adoption supports revenue and helps cover operating costs. Confirmed
- Track enrollment in the Empower BP pivotal study, which has 31 participants and 16 active sites; faster enrollment would move the program toward potential regulatory submission, while delays would extend spending. Proposed
- Monitor the EUR 73.4M cash balance against trial and commercial spending, because a declining balance could pressure the company to raise more money, potentially diluting investors or increasing borrowed money. Analyst inference